GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » Debt-to-Equity

Anteris Technologies (Anteris Technologies) Debt-to-Equity : 0.09 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies Debt-to-Equity?

Anteris Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.66 Mil. Anteris Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.02 Mil. Anteris Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $19.15 Mil. Anteris Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Anteris Technologies's Debt-to-Equity or its related term are showing as below:

AMEUF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09   Med: 0.17   Max: 1.57
Current: 0.09

During the past 13 years, the highest Debt-to-Equity Ratio of Anteris Technologies was 1.57. The lowest was 0.09. And the median was 0.17.

AMEUF's Debt-to-Equity is ranked better than
69.73% of 707 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs AMEUF: 0.09

Anteris Technologies Debt-to-Equity Historical Data

The historical data trend for Anteris Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies Debt-to-Equity Chart

Anteris Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 1.57 0.40 0.11 0.09

Anteris Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.13 0.11 0.14 0.09

Competitive Comparison of Anteris Technologies's Debt-to-Equity

For the Medical Devices subindustry, Anteris Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anteris Technologies's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's Debt-to-Equity falls into.


Anteris Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Anteris Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.655 + 1.023) / 19.145
=0.09

Anteris Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.655 + 1.023) / 19.145
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anteris Technologies  (OTCPK:AMEUF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Anteris Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies (Anteris Technologies) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » Debt-to-Equity
Comparable Companies
ASX:4DX ASX:ARX ASX:IPD ASX:EMV ASX:CYC ASX:IMR ASX:NTI ASX:EYE ASX:CVB ASX:MX1 ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM ZBH ALGN
Traded in Other Exchanges
AVR:Australia
Address
Level 3, 9 Sherwood Road, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Website
https://www.anteristech.com
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.